Rigel Pharmaceuticals (NASDAQ:RIGL) rises 14% in premarket, in reaction to commencement of a Phase 2 trial of fostamatinib, its oral spleen tyrosine kinase inhibitor, for the treatment of hospitalized COVID-19 patients.
The study is sponsored by the National Heart, Lung, and Blood Institute, part of the National Institutes of Health (NIH), in collaboration with Inova Health System.
Fostamatinib, marketed in the U.S. as TAVALISSE tablets, is approved in the U.S. and Europe as a treatment for adult chronic immune thrombocytopenia (characterized by abnormally low levels of platelets).
The study will enroll ~60 patients who require supplemental oxygen. Primary objective of the study is to evaluate the safety of fostamatinib compared to placebo in COVID-19, secondary objective include early efficacy and clinically relevant measures of disease progression.
Treatment will be administered orally twice daily for 14 days, with a follow-up period to day 60.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.